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A literature search, in addition to expert survey, was performed to estimate the size and burden of 
panic disorder in the European Union (EU). Epidemiologic data from EU countries were critically 
reviewed to determine the consistency of prevalence estimates across studies and to identify the most 
pressing questions for future research. A comprehensive literature search focusing on epidemiological 
studies in community and clinical settings in European countries since 1980 was conducted (Medline, 
Web of Science, Psychinfo). Only studies using established diagnostic instruments on the basis of 
DSM-III-R or DSM-IV, or ICD-10 were considered. Thirteen studies from a total of 14 countries were 
identified. Epidemiological findings are relatively consistent across the EU. The 12-month prevalence 
of panic disorder and agoraphobia without history of panic were estimated to be 1.8% (0.7–2.2) and 
1.3% (0.7–2.0) respectively across studies. Rates are twice as high in females and age of first onset for 
both disorders is in adolescence or early adulthood. In addition to comorbidity with agoraphobia, panic 
disorder is strongly associated with other anxiety disorders, and a wide range of somatoform, affective 
and substance use disorders. Even subclinical forms of panic disorder (i.e., panic attacks) are 
associated with substantial distress, psychiatric comorbidity and functional impairment. In general 
health primary care settings, there appears to be substantial underdiagnosis and undertreatment of 
panic disorder. Moreover, panic disorder and agoraphobia are poorly recognized and rarely treated in 
mental health settings, despite high health care utilization rates and substantial long-term disability.   
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1. Introduction  
 
Panic disorder is a severe and persistent mental disorder, associated with a high degree of 
subjective distress, occupational and social disability (Wittchen, 1988; Klerman et al., 1991). 
A panic attack (PA) is the core syndrome (not a codable diagnosis) of panic disorder and is 
defined as a discrete period of intense fear or discomfort accompanied by somatic and psychic 
symptoms, which may or may not be precipitated by exposure to a phobic stimulus (American 
Psychiatric Association, 1994, ICD-10, World Health Organization, 1993). Panic attacks 
typically include acute, somatic symptoms, which can involve cardiovascular, respiratory, 
neurological-like, and gastrointestinal symptoms, sweating, chills and/or hot flushes and 
psychological symptoms (i.e., dizziness, unsteadiness, light-headedness, fear of losing 
control/dying/going crazy). Panic attacks are characterized by sudden onset, rapidly building 
to a peak usually within 10–30 min, and are accompanied by a sense of imminent danger or 
impending doom and an urge to escape.  
 
According to DSM IV (APA, 1994), PD is diagnosed when an individual presents both 
recurrent unexpected panic attacks and at least one of the following: (a) persistent concern of 
having additional attacks, (b) worry about the implications of the attacks and consequences 
(heart attack, dying, losing control) and (c) a significant change in behaviour as a 
consequence of the attack. In addition, the diagnosis of PD requires a complex set of 
differential diagnostic considerations, because the core feature, panic attacks, can also occur 
in many other conditions and situations, such as a direct physiological consequence of 
substance use (i.e., caffeine intoxication) or medical conditions (hyperthyroidism) or in the 
context of other mental disorders (PTSD, social phobia). PD is frequently occurring with 
agoraphobia (PD with agoraphobia), defined as anxiety about being in places or situations 
from which escape might be difficult or embarrassing or in which help might not be available 
in the case that escape is needed. Agoraphobia is characterized by subjective distress and 
marked avoidance of such situations. AG frequently co-occurs jointly with PD, but may also 
occur independently (agoraphobia without PD) (APA, 1994). Panic disorder (PD) and 
associated syndromes and conditions, such as panic attacks (PA) and panic disorder with 
agoraphobia, have been examined in several epidemiological investigations as well as 
systematic international reanalyses of existing data sets.  
 
Several studies examining data from prospective-longitudinal studies in the community have 
focused on panic disorder. Specifically, a number of studies have examined the strength of 
associations between panic disorder and risk for comorbid anxiety, mood, and substance use 
disorders. A number of studies have also examined the role of panic attacks as a core 
psychopathological phenomenon for many mental disorders in an effort to clarify meaningful 
thresholds for defining psychopathology (Reed and Wittchen, 1998; Goodwin and Hamilton, 
2001; Goodwin et al., 2004).  
 
2. Aims  
 
The central aim of this paper is to review epidemiological surveys in the community that 
provide data on panic disorder with and without agoraphobia in Europe, focusing on 
identifying similarities and differences of the prevalence rates from various studies. Further, 
available information on age of onset, comorbidity with physical and mental disorders, and 
burden associated with panic disorder will be reviewed.  
 
3. Methods  
 
A literature search (Medline, Web of Science, Psychinfo) was performed using the following 
key words and related terms: epidemiology, prevalence, incidence, community, general 
population, mental disorders, psychiatric diagnoses/diseases, anxiety, panic attack, panic 
disorder, agoraphobia. The search was run for years 1990 to 2004 (English language or at 
least an abstract in English). The search was restricted to the last two decades because the 
majority of studies from the 1980s were launched in the late 1970s before explicit diagnostic 
criteria were used. Additionally, experts from several countries were contacted to supplement 
the search with results from studies not available via electronic search, and to include papers 
currently in press as well as unpublished data, if accessible. For further details, see Wittchen 
and Jacobi (2005).  
 
4. Results  
 
4.1. 12-Month prevalence of panic disorder and agoraphobia  
 
A total of 13 national or regional studies, as well as one cross-national study involving six EU 
countries, were identified and listed in Table 1. None of the studies was designed specifically 
to study panic disorder. We did not find any epidemiological studies in primary care settings 
or in other mental and non-mental health specialist settings.  
 
The methodological differences between studies need to be taken into account in interpreting 
these findings. Specifically, (a) some studies are based only on highly selective cohorts, for 
example, the Dresden study includes young females only, and the age cohort studies from 
Zurich and Munich refer to specific age groups or adolescence and young adulthood only; (b) 
most studies indicate 12-month prevalence estimates (except for the Dresden and the Great 
Britain study, for which only 1- week cross-sectional rates were reported); (c) seven studies 
used the Composite International Diagnostic Interview (CIDI, Wittchen, 1994), related 
instruments (DIS), or modifications thereof (M-CIDI, Wittchen et al., 1998d) to ascertain the 
diagnostic status. The remaining studies used either the SCAN or study-specific 
developments. The heterogeneity of diagnostic instruments indicates that the studies might 
have used different diagnostic algorithms; (d) the majority of prevalence estimates refer to 
samples with an age range of 18–65. Only one study covers subjects beyond this age.  
 
Accounting for differences in sampling and design, Table 1 reveals a relatively consistent 
pattern of the 12-month prevalence across all studies.  
 
4.1.1. Panic disorder  
 
The majority of findings on the 12-month prevalence of PD cluster around 2% (median across 
studies 1.8%). The two studies investigating 1-week prevalence (Becker et al., 2000; Jenkins 
et al., 1997) reported lower estimates. Lower estimates were also reported from an 
unpublished report from the Czech Republic (0.3%) and the ESEMED study (0.8%). Because 
no confidence intervals were available, however, we were unable to test for significance of 
differences between rates. It appears that studies including a higher proportion of older 
respondents (or fewer younger subjects) tended to have lower estimates. Consistently across 
studies, rates are higher among females (1.0–5.6%) compared with males (0.6–1.5%). Rates 
for panic attacks were reported in only three studies Rates of panic attacks were consistently 
higher among females (2.2% males and 5.6% for females) and at least 2–3 times higher as 
compared with those for full-blown panic disorder (Reed and Wittchen, 1998). The 12-month 
prevalence rates are fairly stable across the age groups and studies. Fig. 1 summarizes the 
findings of the two studies that have reported age-group-related pre-valences, the NEMESIS 
and the GHS-MHS study (Wittchen et al., 2000). Except for different rates of agoraphobia 
among females, the findings from the two studies are consistent.  
 
4.1.2. Agoraphobia  
 
Rates for agoraphobia are difficult to evaluate, because some studies report prevalence rates 
for agoraphobia in general, whereas others only indicate rates for agoraphobia without history 
of PD. As such, there seems to variability in findings. 12-Month total rates vary from 0.4 to 
3.1%; the median across all studies is 1.3% (range 0.7–2.0), gender: male 0.6%, female 1.5%.  
 
4.2. Age of onset, incidence and natural course  
 
A small number of studies have provided detailed data about the age of first onset distribution 
for panic disorder and agoraphobia. Only three of the studies listed (EDSP, Wittchen et al., 
1998b; NEMESIS, Bijl et al., 1998; Zurich, Vollrath et al., 1990) involve a prospective-
longitudinal design to examine prospectively the incidence of panic attacks and panic 
disorder. Most available data on age of onset comes from crude retrospective data that report 
an onset sometimes more than three decades ago. The EDSP and the Zurich cohort studies 
show that PA and PD can begin early, often during childhood or early adolescence (Reed and 
Wittchen, 1998; Wittchen et al., 1998b; Vollrath et al., 1990). The retrospective mean age of 
onset reports for PD is typically in the early to middle 20s (Weissman et al., 1997), with ages 
of onset for agoraphobia slightly higher.  
 
There is evidence of a wide variation and unequal distribution of the age of onset of PD for 
males and females. More detailed hazards analyses on the EDSP data set (Isensee et al., 2003) 
have suggested a unimodal distribution for females with evidence for a fairly steady increase 
in risk for panic attacks occurring after age 10 up to age 28. In contrast, among males, there is 
some evidence for a bimodal distribution. In line with similar findings from the US (Burke et 
al., 1991), there are data suggesting for males a second period of increased risk in the late 40s. 
There are unfortunately no publications describing in greater detail such patterns of incidence 
of panic attacks, PD, and agoraphobia. Studies with incidence data include the Lundby study 
(Grasbeck et al., 1993), the NEMESIS project (Bijl et al., 2002), the Dresden study (Becker et 
al., 2000) and the EDSP project (Wittchen et al., 1998b). Due to the extremely different 
design features (sample composition of various ages and sexes, and differences in the 
incidence observation period, varying from 1–2 years over 4 years to 30 years) between these 
studies, it is impossible to make meaningful comparisons between these studies.  
 
Most studies conducted in clinical settings suggest that PD is generally a chronic condition, 
although with some waxing and waning of the symptomatology (Faravelli and Paionni, 2001). 
In long-term studies, between 17 and 70% of patients still have panic attacks, and between 36 
and 82% have phobic avoidance at follow-up (Katschnig and Amering, 1998).  
 
4.3. Risk factors  
 
Beyond some broad sociodemographic correlates, few potential risk and vulnerability factors 
for PD, PA and agoraphobia with PD have been examined in any of the epidemiological 
surveys reviewed. For panic and agoraphobia, most studies reveal 2- to 3-fold higher rates for 
females as compared to males, although this gender difference seems to diminish – at least in 
some studies – in older age groups due to proportionally higher incidence rates of panic in 
males. Age has been suggested as a risk factor for PD in part due to the observation that rates 
of PD among adults over 60 are considerable lower than those of subjects in the first three 
decades of life. This difference, however, could be due to the fact that standardized diagnostic 
for mental disorders instruments might not be sensitive and valid in the elderly (Knäuper and 
Wittchen, 1994). There is also some speculation of an inverse relationship between PD and 
lower socio-economic status (Kohn et al., 1998), although there is no clear evidence that this 
variable can be regarded as a risk factor as opposed to a correlate of this condition. In 
European studies, no significant association between PD and education, employment status, 
or occupational prestige have been found (Meltzer et al., 1995; Wittchen et al., 1998d).  
 
To our knowledge, there is currently little epidemiological evidence regarding other 
potentially conceptually important risk factors, which have shown to be relevant in clinical 
studies of PD. These include the role of family genetic factors (a family history of PD but 
possibly also of other anxiety and mood disorders), a prior history of childhood anxiety 
disorders including separation anxiety, phobias and overanxious disorder, temperament 
(especially behavioural inhibition), cognitive predispositions such as anxiety sensitivity (a 
tendency to catastrophically misinterpret and fear physiological sensations associated with 
arousal), somatic conditions (especially respiratory illness), early and recent trauma and 
negative life events and parenting styles such as overprotection and rejection (Faravelli and 
Paionni, 2001; Fredman et al., 2003; Zaubler and Katon, 2003).  
 
4.4. Association with other disorders  
 
PD is found to be highly comorbid with a wide range of other mental disorders. This pattern is 
fairly consistent across all available European community studies (Vollrath et al., 1990; 
Wittchen et al., 1998c; Faravelli et al., 2004; Jacobi et al., 2004; The ESEMeD/MHEDEA 
2000 investigators, 2004b). Patterns seem to be identical to those established in international 
studies (Weissman et al., 1997; Roy-Byrne et al., 2000). Significant associations exist with 
almost all anxiety, mood, substance and somatoform disorders. In most of the studies, „pure“ 
PD (i.e., without any comorbid mental disorder) appears to be rare. Most frequent lifetime and 
cross-sectional comorbid patterns were those with depressive disorders, followed by other 
anxiety disorders. According to prospective-longitudinal findings, PD may precede or follow 
other disorders (Roy-Byrne et al., 2000). It is also noteworthy that most studies also report 
increased odds for bipolar disorders (Faravelli et al., 2004) as well as strong associations 
between PD and alcohol/ substance use disorders and somatoform disorders (Merikangas et 
al., 1996; Wittchen et al., 1998b; Faravelli et al., 2004). PD also seems associated with 
various physical disorders, including cardiovascular (Weissman et al., 1990; Mansour et al., 
1998) and respiratory disease (Pollack et al., 1996; Goodwin et al., 2003), vestibular 
dysfunction (Jacob et al., 1996), headache (Marazziti et al., 1999) and irritable bowel 
syndrome (Kaplan et al., 1996).  
 
Available data suggest similarly high comorbidity rates between agoraphobia and mood and 
other anxiety disorders (Wittchen et al., 1998c; The ESEMeD/MHEDEA 2000 investigators, 
2004b). Rarely however have patterns of comorbidity of agoraphobia and comorbid mental 
disorders been studied with similar sophistication and detail as those for PD.  
 
4.5. Panic attacks  
 
Similar to other mental disorders, the current diagnostic criteria for PD have been subject to 
discussions of revisions. For example with regard to (a) definitions for subthreshold or 
sporadic panic attacks (Von Korff et al., 1985; Vollrath et al., 1990), (b) the inclusion of 
specific symptoms (Aronson, 1987) and particularly (c) the relationship between panic attacks 
and panic disorder and agoraphobia (Wittchen et al., 1998b). Some authors – especially those 
from the US – consider panic attacks to be the primary pathological phenomenon and central 
feature of the disorder, with agoraphobia as an avoidance behaviour only secondary to, or 
derived aetiopathogenetically and chronologically secondary to panic disorder (Klein, 1987). 
In fact, DSM-IV considers agoraphobia a residual diagnosis. Others – more consistent with 
traditional European perspectives as codified in the ICD-10 classification – contend that 
agoraphobia occurs with and without panic attacks (Reed and Wittchen, 1998; Wittchen et al., 
1998b). Thus, it is believed that agoraphobia is a separate diagnosis that describe a 
behavioural syndrome reflected by conditioned avoidance to specific phobic situations, 
possibly associated with pathogenic experiences (Marks, 1987; Lelliott et al., 1989). 
Consistent with the latter perspective, epidemiologic studies have shown that panic attacks 
occur in a wide variety of conditions including somatic illness, depression, obsessive–
compulsive disorder, alcohol abuse, borderline states, acute psychosis and in individuals 
without other mental disorders. As a consequence, panic attacks per se are regarded by some 
authors to be a sensitive marker of more severe psychopathology, which becomes 
diagnostically relevant when it occurs under specific conditions (e.g., family genetic 
disposition, pre-existing cognitive patterns, anxiety sensitivity, vulnerability to environmental 
events, coexisting phobic anxiety, temperamental traits) (Wittchen et al., 1998c; Reed and 
Wittchen, 1998; Goodwin and Hamilton, 2001; Goodwin et al., 2004).  
 
4.6. Treatment  
 
Although none of the studies provides a broader description of the health care utilization 
behaviour and the actual treatment rates of panic disorders and agoraphobia, there is some 
evidence that subjects with PD are more likely to seek professional help than subjects with 
other mental disorders. Regarding primary care, a study of five European centres showed that 
60% of the subjects with PD without agoraphobia and nearly 90% of the subjects with PD and 
agoraphobia were recognized as „psychiatric cases“ by their GPs. Only a minority, however, 
were prescribed with anxiolytics or antidepressants (Weiller et al., 1998). In the Health 
Interview and Examination Survey (Jacobi et al., 2004), PD was the most frequently „treated“ 
disorder. Treatment, defined as having contacted a health care professional because of panic 
symptoms at least once, was reported by almost 60% of all subjects with PD. There is also 
evidence that treatment is more likely among cases with comorbidity, such as depression (Bijl 
et al., 2003). A community sample of adolescents and young adults (EDSP, Wittchen et al., 
1998b; Wittchen, 2000) showed that despite high utilization rates, the proportion of patients 
receiving „appropriate“ treatment was extremely low (8%). In this study, appropriate 
treatment was defined as either antidepressant treatment or cognitive–behavioural therapy. 
With the exception of one study, no data on treatment rates for agoraphobia without PD are 
available. This study suggested that patients with agoraphobia might be even less frequently 
recognized and treated than PD (Wittchen et al., 1998a).  
 
4.7. Impairment, disability and other adverse consequences  
 
High levels of disability and impairment and marked reductions in quality of life associated 
with PD are well documented (Faravelli et al., 1989; Vollrath et al., 1990; Wittchen et al., 
1998b). PD ranks among the five mental disorders with the strongest impact in terms of work 
loss days and reduced quality of life. The impact of PD seems stronger than that associated 
with several common chronic physical disorders (The ESEMeD/MHEDEA 2000 
investigators, 2004c). Among adults with PD, even poorer quality of life is predicted by 
comorbid depression, low social support, worry and severity of chest pain (Katerndahl and 
Realini, 1997). PD patients in comparison to controls are at higher risk of suicide as well as an 
increased general morbidity and mortality (Coryell, 1988; Weissman et al., 1989; Lepine et 
al., 1993). However, since PD is frequently comorbid with other psychiatric and somatic 
disorders, these long-term consequences could be attributed to these associated conditions and 
in fact some studies seem to confirm this position (Johnson et al., 1990; Lepine et al., 1993; 
Wunderlich et al., 1998).  
 
5. Discussion  
 
Across the 14 EU countries studies and 13 studies reviewed, the 12-month prevalence rates 
for panic disorder were found to be fairly consistent. 1.8% of the adult population aged 18–65 
was found to suffer from PD. The prevalence of agoraphobia without panic disorder was 
1.3%. Extrapolating these estimates in number of subjects affected and assuming a fairly even 
distribution across all European states, we can estimate that 4.3–5.3 million of the adult EU 
population suffer from PD, and about four million (3.3–4.7) from agoraphobia without panic.  
 
Panic disorder was consistently more common among females (3.0%) compared to males 
(1.7%); for agoraphobia, the gender difference appeared to be even larger (3:1). Across the 
age span 18–65 examined, the prevalence distribution by age group for both conditions 
appeared to be relatively similar. There was agreement from prospective- longitudinal as well 
as retrospective studies that PD may start young as early adolescence or even childhood. The 
majority of all panic cases in the community report an onset before age of 25. Onset 
characteristics for agoraphobia have not been examined in similar detail. Available data 
suggest, however, that the onset might be slightly later in the late 20s. Only two studies have 
provided some evidence of different incidence patterns in males and females (Burke et al., 
1991; Wittchen et al., 1998c). This finding should be considered preliminary and requires 
replication.  
 
Even when controlling for comorbidity, there is also agreement across studies that panic 
disorder with and without agoraphobia is a severe and not infrequently disabling condition, 
associated with increased disability days and social role impairments as well as marked 
reduction in quality of life.  
 
The European findings on the epidemiology of panic disorder are by and large consistent with 
findings in North America (Eaton et al., 1994), South America, and other countries 
(Weissman et al., 1997). In line with the international convergence of findings (Horwath et 
al., 2002), this suggests that PD is cross-culturally much more robust than many other mental 
disorders. Nevertheless, the extrapolation of data from a few European countries to other 
nations, and to Europe as a whole, requires caution and careful examination. It must be noted 
that almost no data are available about the prevalence of PD among various ethnic groups or 
from the new EU membership states. Noteworthy exceptions include data from Hungary and 
the Czech Republic. It should also be highlighted that the epidemiology of agoraphobia has 
received less research attention than PD.  
 
Considerable agreement also exists across studies with regard to high degree of comorbidity 
associated with PD. PD is commonly associated with agoraphobia, as well as a wide range of 
disorders including somatoform, affective, and substance use disorders. Mechanisms 
underlying these high rates of comorbidity are not well understood. Longitudinal studies have 
provided some support for the „symptom progression model“ that hypothesizes that panic is a 
temporally primary condition, leading ultimately to depression and subsequently to self-
medication, resulting in substance use disorders (Klein, 1987; Wittchen, 1988; Wittchen et al., 
1998c). Cross-sectional studies, however, have also shown that panic disorder may occur as 
temporally primary to major depression (Roy-Byrne et al., 2000), as well as a secondary 
condition, or that onsets may even occur simultaneously. Since this issue is of great 
importance for designing preventive measures, further studies are needed to clarify to what 
degree panic is a risk factor for depression and substance abuse.  
 
Despite the consistency in the basic descriptive epidemiological data, several questions 
remain unanswered. These include:  
 
(1) Beyond crude sociodemographic correlates, the vulnerability and risk factors 
constellations for the onset and further progression of panic disorder and agoraphobia have 
not been well-studied and remain poorly understood. Such data are of core importance from a 
public health and prevention perspective. A large number of studies has identified several 
genetic, environmental, psychological and clinical risk factors for PD in clinical samples; 
replication studies in community settings, however, are needed.  
 
(2) Incidence studies that investigate factors associated with onset of panic disorder and 
agoraphobia in different age cohorts are needed. In addition, there is a need for more 
information on the onset of secondary comorbid conditions (e.g., secondary depression or 
substance abuse), among those with PD.  
 
(3) Although clinical wisdom suggests that panic disorder is associated with high utilization 
of health care resources, only anecdotal findings are available for EU countries. Except for the 
WHO collaborative study in primary care (Üstün and Sartorius, 1995) conducted in the 80s, 
the prevalence of these conditions in primary care and specialists settings has not been 
examined. For example, little is known about how frequently PD patients are recognized and 
treated in primary care or specialists settings, or how many receive appropriate drug and/or 
non-drug interventions. Limited evidence from one study suggests that recognition and 
treatment rates of PD are better than those of other mental disorders. Such findings need 
replications from countries with different health care characteristics.  
 
(4) Moreover, data about unmet treatment needs in the European countries with weaker 
economies are of high priority. These issues deserve special attention since several treatment 
options for PD have been shown to be effective and, perhaps even more importantly, cost-
effective. In fact, while adequate psychiatric treatment for PD may increase the direct costs of 
the disorder, they can reduce the total costs when indirect costs (such as work day loss) are 
taken into account (Salvador-Carulla et al., 1995).  
 
In conclusion, while there have been remarkable advances in epidemiologic research in PD 
over the past several decades, important questions remain in at least three general areas.  
 
First, there is a need for increased EU-wide coordination regarding diagnostic assessment 
instruments. Specifically, the establishment of a reliable assessment instrument for future 
European community studies could be used to create a cumulative epidemiological database 
of information on PD in the community. Such a resource could aid in minimizing the degree 
to which differences in current diagnostic methods contribute to inconsistencies in study 
results. Greater attention on obtaining a broader understanding of risk factors for PD onset, as 
well as associated outcomes including help-seeking, utilization behaviour, and disability 
assessment is needed.  
 
Second, there is a need for major incidence studies. These studies should examine both the 
onset of PD, as well as progression and development of comorbidity and disability. These 
investigations should include an investigation of the relationship between PD and the full 
spectrum of mood, anxiety, somatoform and substance use disorders.  
 
Third, there is a need for smaller prevalence studies in the new EU-membership states. Such 
data would help to confirm and extend the data presented here towards determining the level 
of unmet needs for intervention for various types of health care provider models, existing in 
the EU. A systematic assessment in European community residents could provide an 
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